Eris Lifesciences Limited (ERIS.BO)
INR 1321.05
(3.6%)
INR 1321.05
(3.6%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.8 Billion INR | 68.23% |
| 2022 | 8.2 Billion INR | 2347.12% |
| 2021 | 335.37 Million INR | 211.61% |
| 2020 | -300.48 Million INR | 45.43% |
| 2019 | -550.68 Million INR | -132.6% |
| 2018 | 1.68 Billion INR | -53.87% |
| 2017 | 3.66 Billion INR | 21704.19% |
| 2016 | -16.95 Million INR | 79.74% |
| 2015 | -83.68 Million INR | -253.83% |
| 2014 | -23.65 Million INR | -463.29% |
| 2013 | 6.51 Million INR | -65.48% |
| 2012 | 18.86 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 14 Billion INR | 1.45% |
| 2024 Q2 | 25.45 Billion INR | 84.55% |
| 2023 Q1 | 892.43 Million INR | -89.13% |
| 2023 FY | 13.8 Billion INR | 68.23% |
| 2023 Q4 | 13.8 Billion INR | 624.27% |
| 2023 Q3 | 1.9 Billion INR | -70.98% |
| 2023 Q2 | 6.56 Billion INR | 635.96% |
| 2022 FY | 8.2 Billion INR | 2347.12% |
| 2022 Q3 | 709.59 Million INR | -63.46% |
| 2022 Q1 | 2.12 Billion INR | 533.08% |
| 2022 Q2 | 1.94 Billion INR | -8.55% |
| 2022 Q4 | 8.2 Billion INR | 1056.57% |
| 2021 Q3 | 1.48 Billion INR | 8800.42% |
| 2021 Q4 | 335.37 Million INR | -77.45% |
| 2021 FY | 335.37 Million INR | 211.61% |
| 2021 Q1 | 1.36 Billion INR | 554.29% |
| 2021 Q2 | 16.71 Million INR | -98.78% |
| 2020 Q1 | 1.53 Billion INR | 379.14% |
| 2020 Q2 | -423.93 Million INR | -127.58% |
| 2020 Q3 | 2.05 Billion INR | 584.18% |
| 2020 FY | -300.48 Million INR | 45.43% |
| 2020 Q4 | -300.48 Million INR | -114.64% |
| 2019 Q1 | 3.35 Billion INR | 98.55% |
| 2019 Q3 | 2.48 Billion INR | 5242.56% |
| 2019 Q4 | -550.68 Million INR | -122.19% |
| 2019 FY | -550.68 Million INR | -132.6% |
| 2019 Q2 | 46.45 Million INR | -98.62% |
| 2018 Q1 | 1.12 Billion INR | -69.22% |
| 2018 FY | 1.68 Billion INR | -53.87% |
| 2018 Q4 | 1.68 Billion INR | 106.98% |
| 2018 Q3 | 816.14 Million INR | -49.13% |
| 2018 Q2 | 1.6 Billion INR | 42.36% |
| 2017 FY | 3.66 Billion INR | 21704.19% |
| 2017 Q1 | 2.6 Billion INR | 15492.57% |
| 2017 Q4 | 3.66 Billion INR | 37.4% |
| 2017 Q2 | -53.05 Million INR | -102.03% |
| 2017 Q3 | 2.66 Billion INR | 5123.79% |
| 2016 Q2 | -53.08 Million INR | -103.87% |
| 2016 Q4 | -16.95 Million INR | 0.0% |
| 2016 Q1 | 1.37 Billion INR | 0.0% |
| 2016 FY | -16.95 Million INR | 79.74% |
| 2015 FY | -83.68 Million INR | -253.83% |
| 2014 FY | -23.65 Million INR | -463.29% |
| 2013 FY | 6.51 Million INR | -65.48% |
| 2012 FY | 18.86 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -257.133% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -273.823% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 585.686% |
| Granules India Limited | 9.28 Billion INR | -48.667% |
| Indoco Remedies Limited | 6.47 Billion INR | -113.183% |
| Achyut Healthcare Limited | -3.74 Million INR | 368663.534% |
| Ajanta Pharma Limited | -954.9 Million INR | 1545.847% |
| Alkem Laboratories Limited | -1.6 Billion INR | 957.859% |
| Alpa Laboratories Limited | 35.36 Million INR | -38941.908% |
| Brooks Laboratories Limited | 49.48 Million INR | -27800.152% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 375.442% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -318.508% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 1292.517% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | -6.919% |
| FDC Limited | -57.75 Million INR | 24006.341% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 422.183% |
| Gufic Biosciences Limited | 3.19 Billion INR | -332.217% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 432.439% |
| Ipca Laboratories Limited | 11.41 Billion INR | -20.947% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 1093.315% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -614.276% |
| Lasa Supergenerics Limited | 205.79 Million INR | -6608.677% |
| Laurus Labs Limited | 24.38 Billion INR | 43.381% |
| Lupin Limited | 17.19 Billion INR | 19.694% |
| Mankind Pharma Limited | -9.9 Billion INR | 239.346% |
| Medicamen Biotech Limited | 160.31 Million INR | -8511.985% |
| Medico Remedies Limited | 78.67 Million INR | -17448.191% |
| Megasoft Limited | 1.28 Billion INR | -973.966% |
| NATCO Pharma Limited | -5.81 Billion INR | 337.346% |
| Piramal Pharma Limited | 42.27 Billion INR | 67.342% |
| RPG Life Sciences Limited | -364.7 Million INR | 3885.684% |
| Sigachi Industries Limited | 859.94 Million INR | -1505.489% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 119.051% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -9423.225% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -29776.848% |
| Unichem Laboratories Limited | 931.91 Million INR | -1381.506% |
| Wanbury Limited | 1.1 Billion INR | -1148.458% |
| Windlas Biotech Limited | -273.04 Million INR | 5156.545% |
| ZIM Laboratories Limited | 983.6 Million INR | -1303.653% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -252.924% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 1565.958% |
| Divi's Laboratories Limited | -39.77 Billion INR | 134.716% |
| Hester Biosciences Limited | 2.29 Billion INR | -502.704% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 688.006% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 5649.371% |
| Bal Pharma Limited | 1.26 Billion INR | -992.657% |
| Strides Pharma Science Limited | 23.25 Billion INR | 40.636% |
| Venus Remedies Limited | -267.7 Million INR | 5257.411% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -428.596% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -124.228% |
| Shilpa Medicare Limited | 9.06 Billion INR | -52.228% |
| Aarti Drugs Limited | 5.54 Billion INR | -148.836% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 1353.645% |
| Suven Life Sciences Limited | -1.63 Billion INR | 945.618% |
| Ind-Swift Limited | 9.5 Billion INR | -45.199% |
| Valiant Laboratories Limited | -295.03 Million INR | 4779.625% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -389.38% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | -37.665% |
| Themis Medicare Limited | 764.96 Million INR | -1704.847% |
| Hikal Limited | 7.96 Billion INR | -73.295% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 56.625% |
| Sequent Scientific Limited | 4.17 Billion INR | -230.405% |
| Novartis India Limited | -5.89 Billion INR | 334.36% |
| Wockhardt Limited | 18.27 Billion INR | 24.431% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 49.001% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 74947.609% |
| Neuland Laboratories Limited | -214.05 Million INR | 6549.836% |
| Morepen Laboratories Limited | -231.17 Million INR | 6072.294% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -11401.587% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -1314.863% |